The presence of the drug in Oz is generating significant buzz within the medical community. This novel dual agonist – affecting both GLP-1 and GIP receptors – shows a seemingly powerful approach for individuals https://australianpeptidestore.co/bpc-157-10mg-research-peptide-australian-peptide-store/